EVE Health's Libbo ED Film Pilot Study Begins; Results Due End-September

EVE chief executive officer Ben Rohr called the pilot study a key milestone in Libbo's development.

Rohr was appointed CEO in April after serving as chief operating officer, during which he was instrumental in the company's operational and commercial progress. He has also been closely involved in positioning Libbo and Dyspro, a treatment for dysmenorrhea and endometriosis, for regulatory progression and market rollout.

EVE is also developing a reformulated version of the short-acting selective serotonin reuptake inhibitor dapoxetine to treat premature ejaculation, offering improved delivery characteristics. It has designed a dual-acting spray formulation combining vardenafil and dapoxetine for patients experiencing both ED and premature ejaculation, which frequently occur together.

In October, the company raised $1.1 million from sophisticated and professional investors to accelerate the commercial rollout of Libbo and Dyspro.